Home arrow Who Should Take NeuroAiD™?

After a Stroke

NAbox2NeuroAiD™, the treatment for stroke patients

NeuroAiD™ (MLC 601) is a natural medicine indicated for post-stroke rehabilitation. NeuroAiD™ offers a new solution to support stroke sufferers in achieving better neurological and functional recovery.

During stroke recovery, you will be relearning and regaining skills to be as independent as possible. Since your potential to recover will diminish over time, the earlier the right rehabilitation program is initiated, the greater chance you have to recover lost functions.

If you start taking NeuroAiD™

  • Less than six months after the stroke onset:

During this favorable period for recovery, most patients achieve visible progress each month. Clinical trials established that patients taking NeuroAiD™ achieved a significantly better recovery:

Recovering independence: Patients taking NeuroAiD™ more than double their chances to recover independence (by 2.4 times) compared with patients not taking NeuroAiD™.

Reducing disabilities: Patients treated with NeuroAiD™ recover on average 70% of their motor deficits versus 43% for patients not treated with NeuroAiD™. Patients with visual deficits such as homonymous hemianopsia have also shown to revover a further 12% of their visual field on average.

To ensure best results, NeuroAiD™ should be taken together with intense physical therapy.

  • Six months after the stroke onset and beyond:

By this time, many patients may feel left to cope with very slow progress, if any. Yet, experience has shown that adding NeuroAiD™ to the patients’ rehabilitation program can still provide significant improvement and relief.

Many patients tried NeuroAiD™ more than six months after their stroke and reported reduced spasticity and significant improvement in their motor skills, speech, walking, and vision after completing the treatment.

  • Stroke prevention and other neurological diseases:

NeuroAiD™ has not been studied clinically on other indications, but both in vitro and animal testing indicated a prolongation of the life span of neurons against natural aging and further protection against external events. It has also been shown that the surviving neurons are stronger and healthier.

Given its excellent safety profile, we are planning more studies on NeuroAiD™ to evaluate its potential role in slowing down cognitive decline, including Alzheimer’s disease and other neurodegenerative diseases and possibly as an add-on to stroke prevention treatment. This research began in 2012 and will continue this year and beyond.

To receive personal advice on our stroke treatment, please fill up our form and a product specialist will get back to you.

, including Alzheimer Disease,

If you want to know how other patients rated their experience with the NeuroAiD™ treatment, please read our NeuroAiD™ patient survey report by clicking here.

Last Updated on Thursday, 10 May 2012 15:32
 
About Us | Press Releases | Distributors | Terms and Conditions | Privacy Policy | Stroke questions | Blog | Contact us
Copyright © 2003-2013 . All Rights Reserved NeuroAiD™ by Moleac Pte Ltd, Helios #09-08 - 11 Biopolis Way - 138667 SINGAPORE
All Internet orders are secured and processed using SSL. Shipping is handled by FedEx or SingPost according delivery adresses from the Republic of Singapore.
NeuroAiD™ is marketed by Moleac Pte Ltd www.moleac.com This site does not accept any advertisement from third parties except links exchange with few selected websites  Links

Live chat by BoldChat